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Abstract
WHO’s 2015 End TB Strategy advocates social andBackground: 
economic (socioeconomic) support for TB-affected households to improve
TB control. However, evidence concerning socioeconomic support for
TB-affected households remains limited, especially in low-income
countries.
This mixed-methods study in Nepal will: evaluate theProtocol: 
socioeconomic impact of accessing TB diagnosis and care (Project 1); and
create a shortlist of feasible, locally-appropriate interventions to mitigate
this impact (Project 2). The study will be conducted in the Chitwan,
Mahottari, Makawanpur, and Dhanusha districts of Nepal, which have
frequent TB and poverty.
The study population will include: approximately 200 people with TB
(Cases) starting TB treatment with Nepal’s National TB Program and 100
randomly-selected people without TB (Controls) in the same sites (Project
1); and approximately 40 key in-country stakeholders from Nepal including
people with TB, community leaders, and TB healthcare professionals
(Project 2).
1,2 1 1 1
3 4 4
4 1,3 1 2
2 2 3,5 1,3
1
2
3
4
5
   Reviewer Status
  Invited Reviewers
 version 1
05 Feb 2020
 1 2
report report
, London School of HygieneDelia Boccia
and Tropical Medicine, London, UK
1
, University of California SanPriya B. Shete
Francisco, San Francisco, USA
2
 05 Feb 2020,  :19 (First published: 5
)https://doi.org/10.12688/wellcomeopenres.15677.1
 05 Feb 2020,  :19 (Latest published: 5
)https://doi.org/10.12688/wellcomeopenres.15677.1
v1
Page 1 of 13
Wellcome Open Research 2020, 5:19 Last updated: 26 FEB 2020
 During Project 1, visits will be made to people with TB’s households during
months 3 and 6 of TB treatment, and a single visit made to Control
households. During visits, participants will be asked about: TB-related costs
(if receiving treatment), food insecurity, stigma; TB-related knowledge;
household poverty level; social capital; and quality of life.
During Project 2, stakeholders will be invited to participate in: a survey and
focus group discussion (FGD) to characterise socioeconomic impact,
barriers and facilitators to accessing and engaging with TB care in Nepal;
and a one-day workshop to review FGD findings and suggest interventions
to mitigate the barriers identified.
The study has received ethical approval.Ethics and dissemination: 
Results will be disseminated through scientific meetings, open access
publications, and a national workshop in Nepal. 
This research will strengthen understanding of theConclusions: 
socioeconomic impact of TB in Nepal and generate a shortlist of feasible
and locally-appropriate socioeconomic interventions for TB-affected
households for trial evaluation.
Keywords
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Introduction
Tuberculosis (TB) disease, which kills 1.5 million people annu-
ally, is driven by poverty1. Having TB disease can also worsen 
impoverishment through loss of income and costs of access-
ing care2–5. Such costs can become “catastrophic”, leading 
patients to abandon treatment, develop drug-resistance, and die6. 
WHO’s 2015 End TB Strategy advocates elimination of cata-
strophic costs and provision of socioeconomic support for 
TB-affected households5. Nevertheless, there is minimal evi-
dence concerning the ideal interventions to realise this policy 
change6–10. This research will generate preliminary evidence to 
fill this knowledge gap in a low-income country: Nepal. The find-
ings will inform a randomised controlled trial of socioeconomic 
support for TB-affected households in Nepal.
Research from Peru has demonstrated that the severe socio-
economic impact of TB can lead to catastrophic costs (defined 
by WHO as >20% of a household’s annual income)6. The 
same team also demonstrated that socioeconomic interven-
tions for TB-affected households can mitigate catastrophic costs 
(Figure 1a), improve TB preventive therapy uptake (Figure 1b), 
and increase TB treatment success (Figure 1c)11–15.
However, despite these encouraging findings, Peru is a 
middle-income country with a strong TB program and exist-
ing national cash-transfer schemes. To make this research 
replicable and applicable in diverse settings, interventions simi-
lar to those in Peru need to be adapted to other country contexts, 
especially low-income countries (LICs) with less developed 
social protection schemes and high TB burden. One such country 
is Nepal.
The estimated incidence of TB in Nepal is 154/100,000 peo-
ple with 45,000 cases of TB being notified. Amongst these 
cases, there were 6,800 TB-related deaths. Multi-drug resistance 
(MDR) rates were 2.2% in new cases and 15% among retreatment 
Figure 1.  a) Catastrophic costs incurred by intervention (n=135) and control (n=147) TB-affected households of Callao, Peru. b) Preventive 
therapy initiation in household contacts of intervention (n=206) and control (n=204) TB-affected households of Callao, Peru. c) TB treatment 
success in patients from intervention (n=135) and control (n=147) TB-affected households of Callao, Peru. Part a) has been reproduced with 
permission from Wingfield et al.13 Parts b) and c) have been reproduced with permission from Wingfield et al.15.
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cases. Importantly, despite good treatment success rates 
overall of more than 90% reported in Nepal, there remain short-
comings in TB care: treatment success rates were 70% for 
patients with MDR-TB and only 9% for those with HIV-TB 
co-infection; and accessibility of TB care remains low with 
treatment coverage of 70%16.
The poor treatment coverage in Nepal may, in part, be due to 
the financial impact on TB-affected households, which is esti-
mated to be high17. Responding to this estimated burden, the 
Nepal National TB Programme (NTP) national strategic plan for 
2016-2021 identifies provision of a support package to TB-
affected households (specifically targeting MDR-TB-affected 
households) as a priority aim for the country with the goal of 
reducing catastrophic costs. There is currently limited evidence 
concerning the potential acceptability, impact, or cost- 
effectiveness of such a package, with which to inform and guide 
this policy decision. A cohort study has suggested that, dur-
ing their illness, TB patients in Nepal experience decreased 
income and the total costs of accessing free TB treatment 
equate to nearly one quarter of annual household income17. 
Further studies in Nepal have shown that clinic fees make 
up the largest proportion of direct costs and that TB patients 
who are poorer, are migrants, or are from rural areas, experi-
ence a disproportionate burden of total costs18–20. It is vital that 
vulnerable TB patient households most at risk of incurring 
TB-related costs are identified in order to prevent and cure TB 
and mitigate further impoverishment and its consequences. 
In non-randomized studies, incurring higher TB-related 
costs and not receiving education about TB have both been 
found to be associated with worse TB treatment adherence and 
adverse TB treatment outcomes18,21. Therefore, the financial 
impact of having TB disease in Nepal constitutes a challenge to 
achieving TB control and elimination.
To date, no study of TB-affected households’ costs in Nepal 
has been performed using the standardised global methodol-
ogy for measuring costs related to accessing and engaging with 
TB care: the WHO TB Patient Costs Survey22,23. The studies 
above collected data at only one time point rather than repeated 
time points (e.g. cross-sectional rather than longitudinal) 
and did not robustly analyse the socioeconomic posi-
tion, nutritional status, coping strategies, or linkage to social 
protection of TB-affected households. There have been no 
trials of socioeconomic support for TB-affected households in 
Nepal but formative qualitative analysis and a non-randomized 
pilot interventional study (offering education and financial 
support to patients with MDR-TB) suggested improved treatment 
outcomes24.
However, studies reporting quantitative data alone will be insuf-
ficient to influence and change policy. Interaction with and 
among stakeholders has been described as the key facilita-
tor for knowledge translation and evidence-informed health 
policymaking25. These interactions can include policy dialogues 
between stakeholders to deliberate on a priority topic. There-
fore, complementary to quantitative data, the focus group dis-
cussions (FGDs) and workshop detailed within this protocol 
will aim to expand a policy dialogue on socioeconomic support 
for TB-affected households among key stakeholders in Nepal, 
from people with TB to community leaders to TB healthcare 
professionals. Policy dialogues represent knowledge transla-
tion to support the integration of research evidence with tacit 
knowledge of local health policy-makers to: inform future 
policy decisions in often complex and dynamic contexts; and 
foster proactive collaboration26,27. These elements will be critical 
for successful implementation of any future interventions28.
In summary, this mixed-methods research will complement 
and extend the existing knowledge base on social determi-
nants and consequences of TB. More specifically, the culmina-
tion of the research will be the creation of a shortlist of feasible 
and locally-appropriate socioeconomic interventions for 
TB-affected households for future randomized controlled 
trial evaluation in Nepal.
Protocol
Ethical statement
Ethical approval was granted from the University of Liverpool, 
UK, research ethics committee in April 2018 (approval 
number 2436) and then the National Health Research Coun-
cil of Nepal (NHRC) research ethics committee in May 2018 
(approval number 320/2018).
Participant information leaflets will be provided and written 
informed consents will be obtained from all study participants 
for Project 1 Interviews (separate consent forms and infor-
mation leaflets for patients and healthy controls), Project 2 
Surveys, FGDs, and the workshop. These documents are 
available in the Extended Data section attachments29.
All medical records obtained from the Nepal NTP will be kept 
confidential. Practically, through liaison with NTP Project 
Staff (as already organised for IMPACT-TB), the PM, PI, and 
RA will photocopy patient records from the Nepal NTP TB 
register obscuring the patient’s identifiable details. Photocopies 
will be marked with that patient’s unique study number identi-
fier. No individual patients will be identifiable from publications 
resulting from this study.
Study design
This mixed-methods study was funded by a Wellcome Trust 
Seed Award in Science (awards provided to early-career 
researchers to develop a novel idea that will go on to form part 
of a larger grant application) and will be divided into two com-
plementary projects. Project 1 consists of a cohort study 
characterising the socioeconomic impact of TB on TB-affected 
households and a nested case-control study examining the 
social determinants of TB. Project 2 consists of a mixed quan-
titative-qualitative cross-sectional study using surveys, FGDs 
and a workshop to identify the barriers and facilitators to 
accessing and engaging with TB diagnosis and care in Nepal 
and suggesting potential interventions to mitigate the socio-
economic impact and improve access and engagement. The 
study will take place within the infrastructure of the larger 
EU-Horizon 2020 funded “IMPACT-TB” project, which is a 
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study evaluating proven TB active case-finding (ACF) 
interventions in Nepal and Vietnam (grant 733174, http://www.
impacttbproject.org/).
Primary aims
The primary aim of Project 1 is to evaluate the socioeconomic 
impact on TB-affected households of accessing and engaging 
with TB diagnosis and care in Nepal and compare that impact 
in people with TB identified through standard passive case find-
ing (PCF) versus ACF. The primary aim of Project 2 is to 
collaborate with key stakeholders in Nepal to create a shortlist 
of potentially feasible and locally-appropriate socioeconomic 
interventions to mitigate this impact.
Secondary aims
The secondary aim of Project 1 is to compare the social deter-
minants of TB (including socioeconomic position, housing 
situation, knowledge about TB, comorbidities, quality of life, 
food security, and social capital) in people with TB versus 
people without TB from the same districts. The secondary aim 
of Project 2 is to collate the opinions of key stakeholders from 
diverse sectors about barriers and facilitators to accessing and 
engaging with TB care in Nepal.
An additional aim across the study is to generate a policy 
dialogue and form a collaborative research network to sup-
port development and implementation of a future randomised 
control trial of socioeconomic support for TB-affected 
households in Nepal.
Study setting
The study will take place within the infrastructure of the larger 
IMPACT-TB study, which works with a well-established 
international non-governmental organisation, Birat Nepal 
Medical Trust (BNMT), to implement ACF activities includ-
ing sputum-microscopy camps and roll-out of GeneXpert 
OMNI in four intervention and two control districts (with PCF 
only). The four districts are located in the central develop-
ment region of Nepal and were selected for the IMPACT-TB 
project based on comparable populations and TB case detection 
rates (Figure 2).
The primary outcome of IMPACT-TB is the effect of ACF on 
early TB case detection and the study does not involve sup-
port packages for TB-affected households during treatment. 
This presents a unique opportunity for the complementary 
research described in this protocol to add value to IMPACT-TB, 
explore the socioeconomic impact of accessing TB care, 
and shortlist locally-driven strategies to reduce this impact.
Study population
Participant identification, recruitment and follow-up. During 
Project 1, approximately 200 people with TB (cases) con-
secutively recruited to Work Package 3 (WP3) of IMPACT-TB 
Figure 2. Map, population, and TB case notification rate of the four study site districts. Data for population and TB cases notification rate 
shown is taken from the Nepal TB Centre 2018 report. The four study site districts are labelled and highlighted in blue and green.
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(Health Economic Analysis) in the four study sites will be fur-
ther recruited to this study. 100 of these cases will have been 
diagnosed through ACF and 100 diagnosed through PCF. 
Whilst attending the NTP TB clinic, these people with TB will 
be invited to participate in this mixed-methods research with 
a separate written, informed consent (see Project 1 Interview 
Patient Consent Form, Extended data)29. During months three 
and six of their TB treatment, household visits will be conducted 
by BNMT project staff including community mobilisers.
Concurrently, 100 people without TB from the study sites 
(controls) will be invited to participate with written, informed 
consent (see Project 1 Interview Healthy Control Consent Form, 
Extended data)29. Control participants will be approached to 
be invited to participate at diverse locations in the study site 
districts: tea houses, primary healthcare centres, antenatal 
and immunization clinics, door-to-door visits following 
sputum camps (e.g. people who tested negative for TB), and 
public gathering places. Due to constraints in study budget, 
duration, and field logistics, it was not possible to age and sex 
match cases and controls nor to randomly select controls 
using geospatial or other household randomisation techniques.
Project 1 inclusion criteria for Cases included: being a per-
son with TB notified to the NTP and recruited to WP3 of the 
IMPACT-TB study; being aged 18 years or above; and giv-
ing verbal and written informed consent to participate. Project 
1 exclusion criteria for Cases included: being under 18 
years of age; being a person with TB not notified to the NTP 
and/or not recruited to WP3 of the IMPACT-TB study; being 
a person with TB notified to the NTP but with a recorded 
domiciliary address outside of the study site districts; and 
being unable or unwilling to give written and/or verbal informed 
consent to participate.
Project 1 inclusion criteria for Controls included: being 18 
years or above with primary residence in the study site com-
munities; not currently known to be a person with TB or have a 
member of the household currently known to be a person with 
TB (e.g. not diagnosed or notified or receiving TB treatment); 
and giving verbal and written informed consent to participate. 
Project 1 exclusion criteria for Controls included: being under 
18 years of age; not having primary residence in the study 
site communities; known to be a person with TB or have a 
household member with TB currently (e.g. diagnosed and/or 
notified and/or receiving TB treatment); and being unable 
or unwilling to give verbal and written informed consent to 
participate. 
To generate the population for Project 2, a literature review 
and desk-based scoping review will identify a list of key 
in-country stakeholders from Nepal from diverse groups 
including: civil-society representatives; community leaders; 
and TB healthcare professionals including NTP managers and 
multi-disciplinary staff. Approximately 50 stakeholders will be 
selected through purposive sampling and invited to participate 
in: a pre-FGD survey, FGD, and a one-day workshop. A sub-
set of purposively sampled TB patients recruited to Project 1 
(including those with multi-drug resistant TB) will be among 
the stakeholders invited to participate.
Project 2 inclusion criteria include: being aged 18 years or 
above; belonging to a stakeholder group as defined above and/
or identified during scoping exercise; and being able and will-
ing to provide verbal and written, informed consent. Exclu-
sion criteria for Project 2 are not meeting the inclusion criteria 
and/or being a person with TB who has not yet taken two 
weeks of TB treatment or is otherwise considered to still be 
infectious (e.g. MDR-TB with positive sputum smear or culture).
Sample size and statistical power. The sample size for Project 
1 is approximately 200 Cases recruited to WP3 of the IMPACT-
TB project and 100 Controls from the four study site dis-
tricts. This sample size is opportunistic and pragmatic: related 
research suggests that data from 100 people with TB gives a 
representative spread of costs for a given context30,31.
For Project 2, each FGD will consist of approximately eight 
stakeholders. The estimated number of FGDs at which infor-
mation power (or saturation level) will be reached is six12. 
Thus, the sample size for Project 2 is approximately 40 stake-
holder participants. We will invite 55 stakeholders as a con-
tingency because we anticipate an attrition rate of 20–30% 
during the course of Project 2.
Given that this Seed Award research will be exploratory, 
preparatory (e.g. for the future trial), and does not include an 
intervention, no calculations of statistical power are required.
Study interventions
The study will not include any interventions or require any 
patient samples (e.g. blood / sputum / tissue).
Study activities
Broadly, the activities involved in the research will include 
interviews with Cases and Controls during household 
visits, and a pre-FGD survey, FGD, and workshop with key 
stakeholders.
During Project 1, the project team will support BNMT district 
coordinators, community mobilisers, and community volun-
teers to do household visits to approximately 200 Cases with TB 
(100 diagnosed through ACF and 100 through PCF) recruited 
to WP3 of the IMPACT-TB project. People with TB will 
receive two household visits, the first during month three of TB 
treatment and the second visit during month six of TB treat-
ment (to correspond with treatment completion). For con-
trols, a single household visit and interview will be done. 
The interviews will be structured (see Project 1 Interview, 
Extended data)29 and gather data on: i) socioeconomic posi-
tion, evaluated by a multi-dimensional poverty score6,9,13,15 
assessing dwelling characteristics, assets, and access to ameni-
ties; ii) household structure, including distribution of age, sex, 
and employment of household members; iii) food expendi-
ture and security; iv) costs of engaging with TB care including 
direct costs (e.g. medicines, clinic visits, food, and travel) and 
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indirect costs (e.g. lost income), which will be evaluated using 
an adapted version of WHO’s TB Patient Costs Survey inte-
grated into the interview22,23;. v) coping strategies including dis-
saving (e.g. selling assets), schooldays lost, and temporary 
income-generating activities; vi) TB-related knowledge includ-
ing understanding of transmission, prevention, and treatment 
of TB; vii) psychosocial situation evaluated through questions 
relating to social capital, quality of life, and stigma (Controls 
without TB will not be asked any questions about the impact 
that having TB disease has on their psychosocial situation); and 
viii) support for TB-affected households, evaluated through 
use of both closed ranking and open free-text questions to 
establish what socioeconomic and other support people with 
TB and their households receive or would like to receive.
Prior to implementation of household visits, the question-
naire will be translated from English into Nepali and then back-
translated into English. It will be assessed by members of the 
study team and BNMT implementation staff before being 
piloted in approximately 10 patients. The questionnaire may 
subsequently be refined and questions deleted or added, 
depending on the pilot outcomes.
In addition to the above, Cases’ TB treatment outcomes will 
be collated from NTP and IMPACT-TB data and their asso-
ciation with interview responses analysed. This will provide 
an exploratory analysis of the association of socioeconomic 
position, socioeconomic impact of having TB, and TB treat-
ment outcomes. A comparison of the socioeconomic position 
of households of Cases and Controls will also be made.
Project 2 will use and develop mixed methods research 
techniques10–15 to conduct a pre-FGD survey, FGDs, and work-
shop with approximately 40 key stakeholders in Nepal to identify 
the socioeconomic impact, barriers and facilitators to accessing 
and engaging with TB diagnosis and care.
A short individual pre-FGD survey (see Project 2 Survey, 
Extended data)29 will be provided to participants prior to the 
initiation of an FGD. The survey will detail: participants’ 
demographics; the stakeholder group to which the participant 
belongs; and their opinions on community, patient, health sys-
tem, and wider obstacles to achieving successful TB treatment 
outcomes.
The FGDs will be semi-structured and incorporate open-ended 
questions concerning barriers and facilitators to accessing 
and engaging with TB care in Nepal, and existing platforms 
and potential opportunities to mitigate these barriers (see 
Project 2 Focus Groups, Extended data)29. The FGDs will be 
conducted with separate groups of approximately eight key 
stakeholders. Stakeholders will be invited to participate accord-
ing to their background (e.g. people with TB will be asked to 
participate in one FGD, and TB healthcare professionals will 
be asked to participate in another separate FGD). Towards the 
end of each FGD, participants will be asked to privately rank 
the top three most important barriers or facilitators to accessing 
TB diagnosis and care identified by the group during the FGD, 
and these responses will be collated for each FGD and across 
FGDs. The FGDs will be moderated by members of the project 
team trained in qualitative methods including conducting FGDs. 
The discussions will be audio recorded in Nepali language, 
translated into English, and back-translated by a translator who 
is not part of the project team. Each FGD group will be asked 
to elect a representative to feed their group’s outputs back at 
the subsequent workshop.
The final activity in Project 2 will be a one-day workshop bring-
ing together the 40 key stakeholders (see Project 2 Workshop, 
Extended data)29. The morning section of the workshop will 
consist of interactive presentations from the project team and 
stakeholder group representatives, and discussions exploring 
and validating the barriers and opportunities identified during 
the pre-FGD survey and interviews during FGDs. The after-
noon section of the workshop will consist of multi-sectoral 
working groups (≤10 diverse stakeholders) developing a short-
list of potential socioeconomic interventions for TB-affected 
households in Nepal. The interventions will be presented 
to the group including strengths, weaknesses, and potential 
sources of funding for implementation.
Outcomes to be measured
This exploratory Wellcome Trust funded Seed Award in 
Science research in four districts of Nepal will: 
i.    characterise social determinants of TB by comparing 
poverty level, education level, food security, and other 
socioeconomic factors of people with TB (Cases) versus 
people without TB (Controls);
ii.    provide new insight into the barriers, facilitators, 
and socioeconomic impact of being ill with TB and 
accessing TB diagnosis and care, and compare this in 
Cases diagnosed by ACF versus PCF; and
iii.    generate a community-led shortlist of the most feasi-
ble, equitable, and locally-appropriate socioeconomic 
interventions for TB-affected households to mitigate 
the socioeconomic impact of TB.
Data collection and management
During the implementation of Project 1, information will be 
collected by BNMT district coordinators, community vol-
unteers, and community mobilisers with support from the 
project team during visits to recruited patient households. 
This information includes but is not limited to socioeconomic, 
health, psychosocial, and behavioural data. This data will be 
collected on paper due to digital collection (e.g. on tablets or 
mobile phones) having issues with security and feasibility. 
The data of consenting TB patients will subsequently be 
linked with data from NTP’s TB patient register as part of its 
routine surveillance data collection at the intervention and 
control areas, with pre-existing permission from the NTP.
During Project 2, key stakeholders identified by the scop-
ing exercise will complete a short pre-FGD survey in person, 
participate in an FGD, and participate in a one-day workshop.
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All paper-based copies, including medical records, informed 
consent forms and participant information leaflets, will con-
tain only a unique study identifier for each participant. These 
documents will be stored in a locked room in the BNMT office. 
Data will be checked for consistency and completeness by 
the project manager and double-checked by the PI prior to 
entering into an encrypted access database. The database 
will be managed by the data management team at KNCV TB 
Foundation in The Netherlands in line with data collected 
during the IMPACT-TB project. The data will be protected by 
KNCV on a password-secured server with availability limited to 
only key members of the study team when required for analysis.
Data analysis and statistical plan
The quantitative data collected during the household visits of 
Project 1 will be analysed using simple descriptive statistics. 
Continuous costs data will be summarised by their arithme-
tic means and their 95% confidence intervals whether the data 
is Gaussian or non-Gaussian, because this approach is con-
sidered to be robust for health economics data analysis6,32–34. 
Furthermore, because of the skewed nature of some expendi-
ture data, median values may be zero or close to zero limit-
ing the descriptive usefulness of presenting median values. As 
described in the PI’s previous research6, any direct expenses, 
lost income, or annual income recorded as “zero” or miss-
ing will be replaced with the mean cost of each costs category, 
i.e. mean direct costs or lost income. The local currency, 
Nepalese rupee, will be converted into United States Dollars 
(conversion rate and date estimated through Oanda at time 
of data collection). Categorical data will be summarised as 
proportions with 95% confidence intervals.
With regards to analysis of household income and expenditure, 
the WHO TB Patients Costs Survey methods will be followed. 
In order to evaluate the optimal analytical strategy for costs 
data in Nepal, the analysis will compare and contrast the differ-
ent approaches used in the WHO Survey to estimate household 
income (self-reported household consumption; self-reported 
household expenditure; self-reported household income; and 
estimated income based on household asset ownership and 
dwelling characteristics) and lost income (output approach 
of reported income pre- and during TB versus human capi-
tal approach of multiplying hours of work lost by hourly rate or 
daily in rate in cases of hospitalised patients).
Sociodemographic characteristics, socioeconomic position, 
stigma and social capital levels, and TB-related knowledge will 
be compared between ACF patients, PCF patients, and con-
trols using Chi-squared test, Pearson’s test, one-way ANOVA, 
and multiple logistic regression models where appropriate. 
Statistical analysis will be performed using the statistical 
software package STATA v13.1 (Statacorp, TX, USA).
The Framework method of analysis will be used to manage and 
analyse data from Project 2 via the NVivo qualitative software 
package (Version 12) as per published social policy and tuber-
culosis research21–24. Specifically, two researchers (KD and TW) 
will familiarize themselves with the data through successive 
reading of transcripts; use both open and closed first 
order data coding to label data within NVivo; group codes 
together into a second order codebook of themes and sub-themes. 
Themes and subthemes will then be further stratified by third 
order coding to the level at which they predominantly occurred 
(e.g. individual or household level, health systems level, 
community level, or governmental level). Codes, themes, and 
sub-themes will be updated iteratively and flexibly as further 
data becomes available and is collated following each successive 
FGD.
Plans for dissemination of study findings
The intended research outputs of this work are to: i) present 
the interim and final findings at the International Union 
Against TB and Lung Disease in October 2019 and Octo-
ber 2020, respectively; ii) publish, by June 2020, at least two 
papers in high-impact, peer-reviewed journals concerning the 
socioeconomic impact of accessing TB care in Nepal and the 
collaborative development of a shortlist of locally-appropriate 
socioeconomic interventions in Nepal; iii) feedback find-
ings to the IMPACT-TB team, key stakeholders (including 
NTP and TB civil-society), the SPARKS (Social Protection 
Action Research and Knowledge Sharing) network, and WHO; 
iv) consolidate a close collaboration, good working rela-
tionship, and strong research infrastructure between BNMT 
and the NTP; and iv) to develop the protocol for a robust, 
large-scale randomised controlled trial to evaluate socioeco-
nomic support for TB-affected households using the evidence 
generated by this mixed-methods study.
Study status
Data collection for Project 1 during household visits began 
in May 2018 and is nearly complete at the time of writing with 
only TB treatment outcome data still being collected. Data 
collection for Project 2 during pre-FGD surveys and FGDs 
began in August 2018 and was completed in July 2019. The 
national workshop with key stakeholders was conducted on 
11 and 12 September 2019 in Kathmandu, Nepal.
Data analysis, write-up, and dissemination of findings will begin 
in February 2020.
Discussion
The overarching pledge of the Sustainable Development Goals 
(SDGs) is to “leave no one behind”. In 2018, over 3 million 
people with tuberculosis (TB) were not diagnosed, not noti-
fied, or their quality of care was unknown. In the same year, 
1.5 million people with TB died and nearly a fifth of peo-
ple diagnosed with TB did not have a successful treatment 
outcome16. While millions of people with TB continue to be 
left behind, the SDG pledge is far from being realised.
Despite renewed interest in addressing social determinants 
of tuberculosis, there remain stark global inequalities in dis-
ease burden and access to TB care8. At a population level, 
LICs bear the highest TB prevalence16. At an individual level, 
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people with TB are often vulnerable, impoverished, and their 
households suffer disproportionate financial shock due to their 
illness6,13. To eliminate such gross disparity, SDG slogans must be 
turned into actions.
WHO’s 2015 End TB Strategy acknowledges the need to reduce 
inequalities in TB prevention and care. A key component of Pil-
lar 2 (Bold policies and supportive systems) of the strategy is 
social protection and poverty alleviation to reduce catastrophic 
costs of TB-affected households and improve TB outcomes2. 
However, there is minimal evidence to guide this policy change.
This mixed-methods will generate evidence concerning the 
socioeconomic position of TB-affected households, the impact 
that having TB disease has on that position and explore the 
coping strategies that households use to mitigate the impact 
of the disease. Moreover, this research will: use methods to 
measure costs of TB-affected households to which mem-
bers of the study team contributed as part of the WHO Task 
Force on Catastrophic Costs of Tuberculosis; and provide the 
first known comparison of the socioeconomic impact of TB 
on people with TB diagnosed through PCF versus ACF. The 
case-control element of Project 1 will allow comparison of the 
sociodemographic characteristics, socioeconomic position, stigma 
and social capital levels, and TB-related knowledge between 
people with TB (Cases) and people without TB (Controls).
The further significance of the study lies in its development 
of a shortlist of a locally-generated intervention to provide 
socioeconomic support to TB-affected households. Through 
collaboration with diverse stakeholders in Nepal from patients 
to NTP managers to civil-society representatives, it is hoped 
that the shortlist created will feature interventions that are 
both locally-appropriate and feasible. Furthermore, this 
tight collaboration should aid design and implementation of 
a larger, randomised-controlled trial, and also future transla-
tion of research findings into national policy in Nepal. Beyond 
the national impact, these findings and those of the future 
trial will also offer evidence for scale-up of socioeconomic 
support in other resource-limited countries with a high TB bur-
den. Complementary to pills and tests, this socioeconomic 
support will be an essential part of eliminating TB by 2050.
Conclusions
This mixed-methods study will fill this existing evidence gap 
by examining the costs of accessing TB care at a household 
level through longitudinal application of an adapted WHO TB 
Patient Costs Survey throughout TB treatment. This data will 
be enriched by collecting complementary data on household 
socioeconomic position, coping strategies, food insecurity, 
TB knowledge, social capital, and quality of life. The findings 
will then feed into a short survey and semi-structured FGDs 
with key stakeholders in Nepal to consider, at a local, regional, 
and national level, what are the leading barriers and facilitators 
to accessing and engaging in TB care, and what might be the 
most locally-appropriate interventions to address the socioeco-
nomic impact of having TB disease.
Data availability
Underlying data
No data are associated with this article
Extended data
Open Science Framework: Research protocol for a mixed-
methods study to characterise and address the socioeconomic 
impact of accessing TB diagnosis and care in Nepal. https://doi.
org/10.17605/OSF.IO/6TC4F29
This project contains the following extended data: 
-    Final_Wellcome Seed Award Project 1 Patient Interview 
v8.pdf
-    Final Patient _Wellcome Seed Award Project 1 Consent 
Form NEPALI.pdf
-    Final Patient _Wellcome Seed Award Project 1 Interview v8 
NEPALI.pdf
-    Final Patient _Wellcome Seed Award Project 1 Patient Info 
Leaflet NEPALI.pdf
-    Wellcome Seed Award Project 1 Patient Consent Form.pdf
-    Wellcome Seed Award Project 1 Patient Information Leaflet 
ENGLISH.pdf
-    Wellcome Seed Award Project 2 Survey and Focus Group 
Consent Form.pdf
-    Wellcome Seed Award Project 2 Survey and Focus Group 
Participant Information Leaflet.pdf
-    Wellcome Seed Award Project 2 Survey v4 20180525.pdf
-    Wellcome Seed Award Project 2 Workshop Consent 
Form.pdf
-    Wellcome Seed Award Project 2 Workshop Participant 
Information Leaflet.pdf
Data are available under the terms of the Creative 
Commons Zero “No rights reserved” data waiver 
(CC0 1.0 Public domain dedication).
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